Medipurin

Mercaptopurine, the active ingredient in Medipurin, is an antimetabolite (purine analogue) presented as an oral tablet for oral use. It is employed in the treatment of acute lymphoblastic leukemia and certain inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.

GNH USA supplies Medipurin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Medipurin (mercaptopurine) is used in disease areas that involve rapidly dividing cells or immune‑mediated inflammation. - Acute lymphoblastic leukemia (maintenance therapy): helps maintain remission by suppressing leukemic cell proliferation. - Crohn's disease: reduces intestinal inflammation and disease activity. - Ulcerative colitis: controls colonic inflammation and promotes remission.

Common and serious adverse reactions have been reported with mercaptopurine therapy.

Common Side Effects: - Nausea - Vomiting - Loss of appetite - Fatigue

Serious or Rare Side Effects: - Bone marrow suppression leading to anemia, neutropenia or thrombocytopenia - Severe infections due to immunosuppression - Hepatotoxicity with marked liver enzyme elevation - Pancreatitis or hypersensitivity reactions

When prescribing mercaptopurine, clinicians should observe several safety precautions. - Monitor blood counts: perform regular complete blood count tests to detect myelosuppression. - Assess liver function: check hepatic enzymes periodically for signs of toxicity. - Adjust dose in renal impairment: reduce dosage if renal function is compromised. - Avoid use in pregnancy unless essential: drug is classified as Category D and may cause fetal harm. - Store at room temperature below 25°C: keep in the original packaging, protect from moisture and light.

Mercaptopurine may interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Allopurinol: increases mercaptopurine plasma levels and risk of severe bone marrow suppression. - Azathioprine: additive myelosuppressive effect, may require dose reduction. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - NSAIDs: may enhance renal toxicity, requiring renal function monitoring. - Oral contraceptives: may reduce contraceptive effectiveness, advise alternative methods.